PrECOG Cancer Research Group

Dr. Peter O'Dwyer, PrECOG CEO and Chair, and co-author of a new Friends' white paper - Pragmatism in Postmarket Trials - is in Washington, DC, today, attending the Friends’ Annual Meeting 2024. Join us live at the link below to hear the discussion! See below for a link to the white paper. Other topics today: enhancing interim overall survival analyses accuracy and reliability, and advancing ctDNA as an intermediate endpoint in oncology drug development. Meeting link: https://lnkd.in/erimYnVd White paper link: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://lnkd.in/emdGdYH2 #FriendsAM24

Welcome to Premier Health Partners & JPS Health Network, the first two networks to begin enrolling patients in #RealWorldData study PrE1702! PrE1702 is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #lungcancer in patients not participating in a #clinicaltrial. Learn more: https://lnkd.in/em2iy7vw

?? Exciting news in medical research! Real-world data (RWD) will soon be collected on patients with non-small cell lung cancer receiving osimertinib, with or without chemotherapy, in routine clinical practice. This innovative study aims to enhance our understanding of the safety and effectiveness of osimertinib, a newly approved therapy that physicians routinely prescribe. The data collected by PrECOG Cancer Research Group and ECOG-ACRIN Cancer Research Group in this registry will have the potential to provide valuable insights into side effects, patient benefits, survival rates, patient-reported outcomes, and outcomes based on various demographic variables. Stay tuned for updates on this groundbreaking research! ???? #MedicalResearch #Osimertinib #FDA https://lnkd.in/e8vuP63w

Encouraging results for the treatment of mantle cell lymphoma from PrECOG today. The phase 2 trial PrE0405 met its primary endpoint. "With a median age of 60 to 70 years at diagnosis, many patients with mantle cell lymphoma are ineligible for aggressive treatments," said Dr. Craig Portell, who led the study. "In PrE0405, we observed an 85% complete response rate from a lower-intensity therapy." The American Society of Hematology 2023 annual meeting featured the data. #ASH23 https://ow.ly/tsOS50QhzV1